Main Content

Reportable Cancer List DX 10/2018 or later

REPORTABLE CASES – MISSISSIPPI

For cases diagnosed 10/1/2018 and after

The following lists are intended to assist you, as the reporter, in identifying the reportable neoplasms for your facility. Any reportable neoplasms diagnosed on or after January 1, 1996 should be reported to the Mississippi Cancer Registry.

REPORTABLE NEOPLASMS

• Malignant neoplasms (exclusions noted below)
• Benign and borderline neoplasms of the central nervous system (Cases diagnosed on or after January 1, 2004)
• Pilocytic/juvenile astrocytoma listed as 9421/1 in ICD-O-3, is reportable, and should be coded to 9421/3.
• Squamous intraepithelia l neoplasia grade III of vulva [VIN], vagina [VAIN], and anus [AIN] beginning with 2001 cases.
• Carcinoid, NOS of the appendix is reportable and should be coded 8240/3 (Cases diagnosed on or after January 1, 2015)
• Gastrointestinal Stromal Tumor (GIST), NOS with multiple tumor foci and/or metastasis to lymph nodes or distant sites.
• Thymoma, NOS with multiple tumor foci and/or metastasis to lymph nodes or distant sites.
• Malignant GIST and malignant thymomas
• Solid pseudopapillary neoplasm of the pancreas (8452/3) (Cases diagnosed on or after January 1, 2015)
• Cystic pancreatic endocrine neoplasm (CPEN) (8150/3), unless the tumor is specified as a neuroendocrine tumor, grade 1 (assign code 8240/3) or neuroendocrine tumor, grade 2 (assign code 8249/3) (For cases diagnosed January 1, 2015 or later)
• Laryngeal intraepithelia l neoplasia, grade III (LINIII) (8077/2) (C320-C329) (For cases diagnosed January 1, 2015 or later)
• Squamous intraepithelia l neoplasia, grade III (SIN III) (8077/2), except cervix and skin (For cases diagnosed January 1, 2015 and later)
• Mature teratoma of the testes in adults (9080/3) (For cases diagnosed January 1, 2015 and later)

NON-REPORTABLE NEOPLASMS

• Basal and squamous cell carcinomas of the skin (ICD-O-3 Histologies 8090-8110)
• Epithelial carcinomas of the skin (ICD-O-3 Histologies 8010-8046)
• Papillary and squamous cell carcinomas of the skin (ICD-O-3 Histologies 8050-8084)
• Malignant neoplasms, NOS of the skin (ICD-O-3 Histologies 8000-8005)
• Carcinoma in-situ of the cervix
• Intraepithelial neoplasms of the cervix (ICD-O-3 Histology 8077/2) or prostate (ICD-O-3 Histology 8148/2)
• Borderline cystadenomas (ICD-O-3 Histologies 8442, 8451, 8462, 8472, 8473), of the ovaries with behavior code "1" are not collected as of January 1, 2001
• Cyst, brain or CNS tumor that does not have an ICD-O-3 code as of January 1, 2004
• Gastrointestinal Stromal Tumor (GIST), NOS that are not stated to be malignant and are a single tumor with no metastasis to nodes or distant sites
• Thymoma, NOS that are not stated to be malignant and are a single tumor with no metastasis to nodes or distant sites
• Severe dysplasia of any site including the Gastrointestinal There must be a statement that this is carcinoma in situ to be reportable.
• Mature teratoma of the testes in prepubescent children (9080/0)

AMBIGUOUS TERMINOLOGY

** Do not substitute synonyms such as "supposed" for "presumed" or "equal" for "comparable." Do not substitute "likely" for "most likely." Use on the exact words on the list.

Exceptions:

• If a cytology is reported using any ambiguous term, do not interpret it as a diagnosis of cancer. Abstract the case only if a positive biopsy or a physician’s clinical impression of cancer supports the cytology
• Genetic findings in the absence of pathologic or clinical evidence of reportable disease are indicative of risk only and do not constitute a diagnosis.

COMPREHENSIVE ICD-10-CM CASEFINDING CODE LIST FOR REPORTABLE TUMORS

¹ Note: Pilocytic/juvenile astrocytoma M-9421 moved from behavior /3 (malignant) to /1 (borderline malignancy) in ICD-O-3. However, these cases should be reported and behavior coded as /3 (malignant).

SUPPLEMENTAL CASEFINDING LIST TO BE SCREENED FOR REPORTABLE CONDITIONS

Cases with the following codes should be screened as time allows. Experience has shown that use of this supplemental list increases casefinding for benign brain and CNS, hematopoietic neoplasms and other reportable diseases